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Objective
To evaluate the consistency of response to eletriptan in
migraine.
Background
Surveys indicate that more than 40% of individuals have
an average headache frequency of 2 or more attacks per
month. Lack of consistent response has been cited in
patient surveys as one of the top 3 reasons for dissatisfac-
tion with migraine treatments.
Methods
Patients first completed an open-label, lead-in period in
which they treated 3 migraine attacks with eletriptan 40 mg.
Based on response to open-label treatment, patients
were treated with either eletriptan 40 mg (E40; N=539) or
eletriptan 80 mg (E80; N=432) in a 4-attack consistency of
response study in which placebo was substituted, in a
randomized, double-blind fashion, for the treatment of one
attack. Headache response was defined as improvement at 2
hours post-dose to a headache intensity of none (pain-free)
or mild. Within-patient consistency was defined a priori as
headache response at 2 hours on at least 2 out of 3 attacks.
Results
During double-blind treatment, within-patient consis-
tency was 77% for E40 and 73% for E80. For patients
(N=47) who had responded to 0/3 attacks on E40 in the
open-label phase, titration to the E80 dose resulted in
headache response in 55%. A repeated measures logistic
regression analysis found that sustained headache
response at 24 hours, averaged across 3 attacks, was sig-
nificantly higher on both E40 vs. placebo (49% vs. 32%;
p < 0.001) and E80 vs. placebo (43% vs. 11%; p < 0.001).
Sustained pain-free at 24 hours, averaged across all 3
attacks, was also significantly higher on both E40 vs.
placebo (30% vs. 5%; p < 0.001) and E80 vs. placebo
(25% vs. 3%; p < 0.001).
Conclusion
Eletriptan showed consistent and sustained efficacy in
the treatment of migraine. Funded by Pfizer Inc.
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